In a year of flashy growth stocks, two Dividend Kings have quietly outperformed the market. AbbVie (ABBV) has seen its stock soar 29% YTD, driven by strong revenue growth and dividend increases. With a diverse portfolio and robust performance in immunology and neuroscience, AbbVie continues to deliver for investors. Johnson & Johnson (JNJ) reported impressive third-quarter sales of $24 billion, showcasing operational growth across key brands like DARZALEX and TREMFYA. As a long-standing Dividend King, JNJ’s commitment to shareholders and consistent growth have positioned it as a market outperformer. Analysts rate both stocks as a “Moderate Buy” with significant upside potential.

Read more at Barchart.: 2 Dividend Kings Quietly Beating the Market This Year